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 Patient: Female, 63
 Final Diagnosis: Drug-induced hyponatremic encephalopathy
 Symptoms: Seizures • coma
 Medication: Hypertonic 3% saline infusion
 Clinical Procedure: —
 Specialty: Internal Medicine
 Objective: Unusual clinical course
 Background: Drug-induced hyponatremia characteristically presents with subtle psychomotor symptoms due to its slow on-
set, which permits compensatory volume adjustment to hypo-osmolality in the central nervous system. Due 
mainly to the syndrome of inappropriate antidiuretic hormone secretion (SIADH), this condition readily resolves 
following discontinuation of the responsible pharmacological agent. Here, we present an unusual case of life-
threatening encephalopathy due to adverse drug-related effects, in which a rapid clinical response facilitated 
emergent treatment to avert life-threatening acute cerebral edema.
 Case Report: A 63-year-old woman with refractory depression was admitted for inpatient psychiatric care with a normal 
physical examination and laboratory values, including a serum sodium [Na+] of 144 mEq/L. She had a grand 
mal seizure and became unresponsive on the fourth day of treatment with the dual serotonin and norepineph-
rine reuptake inhibitor [SNRI] duloxetine while being continued on a thiazide-containing diuretic for a hyper-
tensive disorder. Emergent infusion of intravenous hypertonic (3%) saline was initiated after determination of 
a serum sodium [Na+] of 103 mEq/L with a urine osmolality of 314 mOsm/kg H20 and urine [Na
+] of 12 mEq/L. 
Correction of hyposmolality in accordance with current guidelines resulted in progressive improvement over 
several days, and she returned to her baseline mental status.
 Conclusions: Seizures with life-threatening hyponatremic encephalopathy in this case likely resulted from co-occurring SIADH 
and sodium depletion due to duloxetine and hydrochlorothiazide, respectively. A rapid clinical response expe-
dited diagnosis and emergent treatment to reverse life-threatening acute cerebral edema and facilitate a full 
recovery without neurological complications.
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Background
Drug-Induced hyponatremia is a frequent and potentially seri-
ous adverse reaction with many psychopharmacological agents, 
mediated in most cases by the syndrome of inappropriate an-
tidiuretic hormone secretion (SIADH) [1–3]. This condition most 
often leads to subtle psychomotor symptoms due to its slow 
progression, permitting a compensatory adjustment of intra-
cellular volume in the central nervous system. Subtle psycho-
motor symptoms and motor imbalance readily resolve after 
discontinuation of the responsible pharmacological agent [4]. 
In contrast, rapid onset of hyponatremia may present with 
life-threatening encephalopathy, which requires emergent in-
fusion of intravenous hypertonic (3%) saline to reverse acute 
cerebral edema.
We describe herein a patient presenting with seizures 4 days 
after initiating treatment with the dual serotonin and norepi-
nephrine reuptake inhibitor [SNRI] duloxetine, with continua-
tion of a thiazide-containing diuretic for a stable hypertensive 
disorder. Laboratory data determined that SIADH and sodi-
um depletion were collateral underlying causes of this atyp-
ical presentation related to duloxetine and hydrochlorothia-
zide, respectively. A rapid clinical response expedited diagnosis 
and emergent treatment, averting potentially fatal acute ce-
rebral edema and facilitating a full recovery without neuro-
logical complications.
Case Report
A 63-year-old white woman was hospitalized for refracto-
ry depression. Physical exam was unremarkable and labo-
ratory values were normal, including a serum sodium [Na+] 
of 144 meq/L. Treatment was initiated with the SNRI du-
loxetine and titrated to 40 mg daily over several days while 
triamterene/hydrochlorothiazide 37.5/25 mg daily was contin-
ued for a stable hypertensive disorder. Her daily sodium intake 
was 5 grams and she had no sign of a thirst disorder. Seizures 
and unresponsiveness led to an emergent evaluation showing 
a [Na+] of 103 mEq/L, potassium 3.5 mEq/L, chloride 76 mEq/L, 
BUN 15 mg/dL, creatinine 0.7 mg/dL, C02 of 16 mEq/L, anion 
gap 13, lactic acid 4.4 mg/dL, urine osmolality 314 mOsm/kg 
H20, and urine [Na
+] 12 mEq/L. Emergent infusion of intrave-
nous hypertonic (3%) saline according to current clinical guide-
lines resulted in progressive improvement over several days 
and a return to her baseline mental status without neurolog-
ical complications.
Discussion
As the most common electrolyte abnormality in medical prac-
tice, recent evidence from meta-analyses indicates that hypo-
natremia, defined as a reduction in the serum sodium concen-
tration (Na+)<135 mEq/L, is associated with increased morbidity 
and excess mortality [1,2]. Psychiatric patients are at substan-
tial risk for this adverse event, which may occur with many 
pharmacologic agents. SIADH is the most common underly-
ing mechanism, accounting for over 80% of cases in psychi-
atric patients in contrast to less than 30% in general medi-
cal practice [3].
SIADH characteristically results in subtle changes in mental 
status, psychomotor deficits, and motor instability with an in-
creased risk for falling. Optimal treatment of symptomatic hy-
po-osmolar hyponatremia begins with a high index of suspi-
cion and identification of the underlying cause as determined 
by simultaneous measurement of serum and urine chemis-
try (Table 1) [4,5]. Hyponatremia due to SIADH results in less 
than maximally diluted urine, with an osmolality greater than 
100 mOsm/kg H2O and a urine [Na
+] greater than 30 mEq/L. 
Hypo-osmolar 
hyponatremia
Blood urea nitrogen 
(mg/dL)
Urine osmolality 
(mOsm/kg H20)
Urine sodium 
(mEq/L)
AVP 
(ng/L)
Dilutional
• Polydipsia
• SIADH
<15
<15
<100
>100 
Variable
>30
<1.0
>1.0
Depletional >15 >300 <30 <30
Table 1. Pathophysiologic findings in hypo-osmolar hyponatremia: Differentiation of dilutional versus depletional mechanisms.
The underlying mechanism of hypo-osmolar hyponatremia can be assessed according to laboratory criteria. Dilutional hyponatremia 
due primarily to polydipsia produces a maximally dilute urine with a variable (Na+) and suppression of AVP secretion. Dilutional 
hyponatremia under conditions of SIADH results in a concentrated urine with a sodium value >30 mEq/L and an inappropriate urinary 
response to hypo-osmolality. Depletional hyponatremia associated with dehydration [BUN >15 mg/dL] leads to concentrated urine 
with a sodium value <30 mEq/L and volume-dependent stimulation of AVP secretion. AVP – arginine vasopressin; SIADH – syndrome 
of inappropriate antidiuretic hormone secretion. (Adapted from: Siegel AJ: Is urine concentration a reliable biomarker to guide vaptan 
usage in psychiatric patients with symptomatic hyponatremia? Psychiatry Res, 2015; 226: 403–4).
151
Siegel A.J. et al.: 
Drug-related hyponatremic encephalopathy…
© Am J Case Rep, 2016; 17: 150-153
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License
Symptoms resolve rapidly after discontinuation of the respon-
sible agent. In contrast, the rapid onset of hyponatremia, as 
seen in patients with polydipsia, results in maximally diluted 
urine with a variable sodium content. Sodium depletion results 
in high urine osmolality with a low urine [Na+] concentration 
and elevated BUN in the presence of co-occurring dehydration.
Taking laboratory findings into account in this case, the urine 
osmolality of 314 mOsm/kg H20 indicates that the SIADH was 
likely related to the SNRI duloxetine, while the urine [Na+] of 
12 mEq/L represents sodium depletion likely due to hydrochlo-
rothiazide. The co-occurrence of SIADH and sodium depletion 
likely accounts for the uncharacteristically severe onset of life-
threatening hyponatremic encephalopathy in this case, with a 
higher degree of clinical severity than has been reported pre-
viously with either SNRI-induced SIADH or thiazide-induced 
hyponatremia alone [6]. Co-administration of pharmacologi-
cal agents conferring risk for dilutional hyponatremia by var-
ious mechanisms should therefore be avoided.
Treatment of symptomatic hyponatremia is guided by the lev-
el of clinical severity, as shown in an algorithm based on re-
cent best-practices guidelines (Figure 1) [7,8]. Emergent in-
fusion of intravenous hypertonic (3%) saline is indicated for 
severe neurological symptoms to rapidly reverse the flow of 
water in the brain in response to increased blood osmolality. 
Current guidelines call for a rate of correction with a maximal 
increase in [Na+] of 8–10 mEq/L in the first 24 hours to avoid 
the complications of osmotic demyelination syndrome or cen-
tral pontine myelinolysis [9,10].
Treatment with vasopressin receptor blockers as pure aquaretic 
agents may be indicated with moderate symptoms, as shown 
to be efficacious and safe for patients with SIADH [11,12]. A 
summary of current treatment practices based on an interna-
tional registry showed a greater likelihood of meaningful cor-
rection of hyponatremia with these agents compared to alter-
native therapies [13,14]. The finding of a urine concentration 
above 219 mOsm/kg has been identified as a potentially re-
liable biomarker for the efficacy of vaptan usage unless pre-
cluded, as in this case, by the degree of clinical severity [15,16].
Conclusions
A rapid clinical response to the abrupt onset of seizures expe-
dited diagnosis and emergent treatment, reversing acute ce-
rebral edema and facilitating a full recovery without neuro-
logical complications. Clinicians prescribing pharmacological 
agents conferring risk for dilutional hyponatremia should main-
tain a high index of suspicion for the full spectrum of conse-
quent clinical severity.
Conflicts of interest
None.
Figure 1.  Algorithm for Treatment of 
Hyponatremia Guided by Clinical 
Severity 1. Treatment of dilutional 
hyponatremia in psychiatric patients. 
* The severity of symptoms is 
related to the rate of development 
of the hypo-osmolality; the serum 
[Na+] at which symptoms appear 
varies markedly among individuals, 
although most patients demonstrate 
symptoms when the serum [Na+] 
falls below 125 mEq/L. ** The rate of 
correction of hyponatremia should 
not exceed a maximum of 10 to 12 
mEq/L in 24 hours. Adapted from: 
Siegel AJ: Hyponatremia in psychiatric 
patients: update on evaluation and 
management. Harv Rev Psychiatry, 
2008; 16: 13–24.
Neurologic Symptoms
Acute hyponatremia
Encephalopathy, delirium, seizures,
coma*
Chronic hyponatremia
Headache, lethargy, unsteadiness,
nausea
• Hypertonic (3%) saline at 1 mL/kg/h
   until clinical imrpovement and serum
   [Na+] increases by 4 to 6 mEq/L**
• Administer a bolus dose (100 mL
   hypertonic [3%] saline) in those with
   seizure or in come
• Coadministration of IV furosemide
   (20–40 mg) for volume overload
• Adequate ventilation if necessary
• Resrtict fluid intake (<1 L/day)
• Identify and treat reversible cause, such
   as drug-induced SIADH
• AVP-receptor antagonist**
• Consider other treatments (clozapine
    and demeclocycline)
Emergency correction required Gradual correction only
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